Florida based 21 Medical Technologies LLC.,' (21 MT) will exclusively market and distribute INJEX Pharma's INJEX30 Systems in the United States. INJEX30 syringes without a needle may be used in multiple medical, cosmetic and anaesthetic applications and marketed via traditional pharmaceutical and emerging life science modalities.

INJEX30 targeted disease states and delivery systems include diabetes, local and dental anaesthetics, allergy and fertility treatments, vaccinations, erectile dysfunction and growth hormones.

“21 MT is a perfect partner in the US and it's an exciting time for INJEX Pharma AG as we continue to execute on our global mission while simultaneously introducing the SHIREEN Beauty Kit utilizing a 'Poring method' in the United States,” said Andy Rösch, CEO INJEX Pharma AG.

The signed distributor agreement includes a minimum volume of 70,000 INJEX30 Systems, 25,000 SHIREEN Beauty Kits and 300,000 SHIREEN Fluid Units. The First shipment will commence during the month of September.

“Product launches in the United States must be carefully orchestrated across many modalities including direct to the consumer. The United States' healthcare industry appears to be in early stages of its transformation which presents an opportune time to align our innovative technology with a 'High profile personality.' '21 MT' has the ability to raise immediate awareness for both INJEX30 Systems and SHIREEN Beauty Kits through its media reach and seasoned team of professionals. We look forward to working closely with '21 MT' as they prepare to deploy significant resources across modalities. This multi-faceted approach will be necessary to build brand awareness with an emphasis on 'service excellence.' This agreement is a 'Home run' for the end users who will benefit from a syringe delivery system without a needle,” said Sylwin Grinman, Director International Sales and Marketing at INJEX Pharma AG.

“We are excited to begin marketing our innovative 'Poring method' with SHIREEN Beauty Kits in the world's biggest beauty market. '21 MT' was founded with an appreciation for challenges when dealing with big markets and we are comfortable '21 MT' will exceed distribution expectations and establish new benchmarks for 'service excellence' in this industry. We will be increasing our production capacities in the short-term and developing necessary logistical contingencies to meet future demand. '21 MT' will consummate this agreement in the days ahead, with payments on the way, triggering exclusivity, as terms for initial shipments are met. Shortly thereafter, we expect to conduct a press conference with 21 Medical Technologies LLC, elaborating on our vision, steps for executing in the US and defining details related to this agreement,” said Andy Rösch, CEO INJEX Pharma AG.

The INJEX Pharma AG is a manufacturer and distributor of innovative and sustainable health solutions. Product focus are currently needleless injection systems and exclusive agents.